Goldman Sachs Call 180 MRK 17.01..../ DE000GZ98XV1 /
01/11/2024 9:22:21 | Diferencia- | Bid22:00:27 | Ask22:00:27 | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
0.001EUR | - | - Volumen de oferta: - |
- Tamaño/ Volumen/ Formato de Ask: - |
Merck and Co Inc | 180.00 USD | 17/01/2025 | Call |
GlobeNewswire
31/07
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
17/07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
11/06
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
28/05
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
23/05
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
16/05
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
14/05
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
08/05
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
24/04
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
15/04
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página